Shionogi 1H FY18 (YE Mar'19) Results - First Glance
Key highlights 1H FY18 gross margins improved significantly to 85.3% from ~77% for the same period last year, primarily driven by 24% increase in...
394 Views
Opportunities in The (Overpriced) Japan Pharma Sector
As a defensive sector, Japan’s pharmaceutical sector has had an up-and-down time of it during the Abe era. In the early days of Abenomics, the...
267 Views
Innovation to Help Maintain HIV Franchise Market Share and Weather Harsh Domestic Market Conditions
Continuous innovation at HIV Franchise to not only help defend market share…. Concerns about competition from Gilead Sciences Inc (GILD US)'s,...
297 Views
Shionogi FY17 Earnings - First Glance
Shionogi & Co Ltd (4507 JP) reported FY17 results on May 09, 2018 HIV franchise royalties drove FY17 topline growth and gross margin expansion...
182 Views
Japan Pharma: Upcoming Catalysts & Event Driven Trading Ideas
Takeda Pharmaceutical Co Ltd (4502 JP), Shionogi & Co Ltd (4507 JP), Nippon Shinyaku Co Ltd (4516 JP) , Sumitomo Dainippon Pharma Co (4506 JP),...
316 Views